|
|
|
|
Only 49 cell and gene therapies have reached approval despite 5,000+ active clinical trials. Closing that gap requires designing for commercial-scale manufacturing from the earliest research decisions, not retrofitting later.
|
|
|
|
|
Variability in autologous starting materials, serum-based media, and ill-matched early-stage platforms are among the biggest obstacles to commercial-scale cell therapy manufacturing. Getting these decisions right early is the difference between a therapy that reaches patients and one that doesn't.
|
|
|
|
|
Reducing variability is critical to advancing cell therapy development. Learn how cell sourcing, quality-focused manufacturing strategies, and ecosystem partnerships can support reproducible research.
|
|
|
|
|
|
|
|
|
|
|
Consistent MSC research starts with controlling variability. Cell sourcing and optimized cryopreservation strategies can improve process control for umbilical cord-derived cell therapy development.
|
|
|
|
|
|
|
|
|
FUJIFILM Biosciences and NextCell Pharma AB have partnered to provide researchers with a standardized platform for umbilical cord -derived MSC research. Introducing NextCell-Cord RUO a research-use-only (RUO) UC-MSC product designed to support translational research and process development. Available as a standalone cell source or bundled with PRIME-XV MSC Expansion XSFM media and cryopreservation solutions, the platform is designed to help simplify MSC workflows from sourcing through expansion. Learn more.
|
|
|
